Key Growth Drivers & Emerging Applications
The Erythropoietin Drugs Market is driven by rising incidences of anemia from chronic illnesses and growing accessibility in developing markets. Healthcare providers increasingly prefer erythropoietin therapies over blood transfusions due to improved safety and patient compliance.
Beyond traditional anemia indications, emerging research explores erythropoietin’s potential in neuroprotection (e.g., neonatal hypoxic injury) and other novel therapeutic areas, setting the stage for broader clinical applications in the near future.
3 Views